Biotech and Pharmaceuticals Pharmaceuticals

  • Deutsche Bank plunged as investors worried about the financial health of Germany's largest bank. Pfizer pulled drugmakers down after it announced it won't break up into two companies. European banks tumbled after the German magazine Focus said Deutsche Bank won't get a government bailout if it asks for one.

  • TOKYO, Sept 26- Japan's Nikkei share average dropped on Monday morning, with sentiment soured by a strong yen and weakness on Wall Street, while investors turned their focus to the U.S. presidential debate. Anything triggering fears for a strong yen trend is negative to stocks, "said Takuya Takahashi, a strategist at Daiwa Securities. Takahashi also noted that the...

  • Amjevita is the fourth biosimilar to be approved by the FDA and is expected to be sold at a discount to the original drug. Unlike generics, which are interchangeable with their branded counterparts, biosimilars approved by the FDA to date are not considered interchangeable and therefore are not called generic. The FDA has determined, however, that there is no...

  • The Food and Drug Administration cleared a near-copy of the drug, dubbed Amjevita, developed by Amgen Inc. Regulators approved the drug for more than a half-dozen conditions listed on the original drug's label, including severe psoriasis and Crohn's diseases. But currently only one biosimilar cleared by the FDA approval pathway is actually on the market in...

  • Amjevita is the fourth biosimilar to be approved by the FDA and is expected to be sold at a discount to the original drug. Unlike generics, which are interchangeable with their branded counterparts, biosimilars approved by the FDA to date are not considered interchangable and therefore are not called generic. The FDA has determined, however, that there is no...

  • Drugs are prepared to shoot intravenously by a user addicted to heroin in St. Johnsbury Vermont. (File photo).

    The cost of naloxone has spiraled upwards, even as the drug has become more desperately needed to reverse overdoses.

  • SAN FRANCISCO, Sept 23- Who becomes the next U.S. president will be a primary focus for Wall Street next week and beyond, starting on Monday with the first debate between candidates Hillary Clinton and Donald Trump. While the White House race has so far had little discernible effect on the market, that may soon change as polls show a tightening race.

  • Yahoo Inc., down $1.35 to $42.80. Endo International PLC, up $3.13 to $23.39. Oshkosh Corp., down $6.02 to $50.88.

  • Sept 23- Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli, as the drugmaker grapples with a large debt load and mounting pressure on some of its drug prices. Endo's shares rose as much as 18 percent to $23.98 on Friday as the company also maintained its full-year profit and...

  • Sept 23- Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli, highlighting the drugmaker's shift away from specialty branded drugs. Endo's shares rose as much as 18 percent to $23.98 on Friday as the company also maintained its full-year profit and revenue forecasts.

  • Sept 23- Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli, highlighting the drugmaker's shift away from specialty branded drugs. Endo's shares rose as much as 16 percent to $23.48 on Friday as the company also maintained its profit and revenue forecasts for the year.

  • NEW YORK— Pfizer expects to complete its $14 billion buyout of cancer drug developer Medivation in the third quarter following the expiration of a regulatory waiting period. The New York drugmaker has agreed to pay $81.50 per Medivation share, which marked a 21 percent premium to San Francisco- based Medivation's closing price when it was announced in August.

  • Sept 23- Drugmaker Endo International Plc said on Friday Chief Executive and President Rajiv De Silva had stepped down, and named Paul Campanelli as his successor. Campanelli joined Endo in 2015 following its acquisition of Par Pharmaceutical, where he served as CEO since 2012.. Shares of Endo, which backed its third quarter and full-year financial guidance,...

  • Diabetes emerging trend in drug development

    Alex Gunz, fund manager at Heptagon Capital, explains why he favors Novo Nordisk and Tupperware, saying that emerging markets are key to their success.

  • According to the lawsuit by the states, Indivior told the FDA that it planned to offer a new "sublingual film," or dissolvable strip version of the drug, which had been licensed to Indivior by MonoSol Rx. The lawsuit claims that the company persuaded the FDA to approve the strip by raising concerns that the tablet posed high exposure risks to children.

  • SAN FRANCISCO— Thirty-five states and the District of Columbia filed an antitrust lawsuit Thursday alleging that British drugmaker Indivior tried to keep cheaper, generic versions of Suboxone off the market, California's attorney general announced. The complaint filed in the U.S. District Court for the Eastern District of Pennsylvania also names New...

  • According to the lawsuit by the states, Indivior told the FDA that it planned to offer a new "sublingual film," or dissolvable strip version of the drug, which had been licensed to Indivior by MonoSol. The lawsuit claims that the company persuaded the FDA to approve the strip by raising concerns that the tablet posed high exposure risks to children.

  • WASHINGTON, Sept 22- Thirty-five U.S. states and the District of Columbia filed a lawsuit on Thursday against opioid drug maker Indivior alleging it tried to keep generic versions of a drug off the market. British-based Indivior, which was spun off from Reckitt Benckiser in 2014, is the maker of Suboxone, a drug used to treat patients addicted to heroin and other...

  • The Copenhagen- based company said on Thursday both doses of the drug, idalopirdine, showed a "weak efficacy profile" and failed to reduce cognitive decline measured on a scale called ADAS-cog in the study named Starshine. Idalopirdine, which is being developed with Japan's Otsuka Pharmaceutical Co Ltd, is being tested in patients with mild to moderate...

  • The company was testing the drug in combination with donepezil, a compound that forms the core of Pfizer Inc's Alzheimer's treatment Aricept. The Copenhagen- based company said both doses of idalopirdine, which is being developed with Japan's Otsuka Pharmaceutical Co Ltd, also failed to meet the secondary goals of the study. Anders Gersel Pedersen, Chief...